Abstract
Autologous haematopoietic stem cell transplantation (AHSCT) is a promising treatment for multiple sclerosis (MS) patients who have not adequately responded to conventional therapies. We retrospectively evaluated the safety and long-term clinical outcome of AHSCT in MS patients in China. Twenty-five patients with various types of MS were treated with AHSCT. Peripheral blood stem cells were derived by leukapheresis after mobilized with granulocyte colony-stimulating factor. Then CD34+ cell selection of the graft was performed and anti-thymocyte globulin was given for T-cell depletion, with the conditioning regimen BEAM adopted and early and late toxicities recorded. Long-term responses were evaluated by the expanded disability status scale (EDSS), progression-free survival and gadolinium-enhanced magnetic resonance imaging scans. 10, 7 and 8 patients experienced neurological improvement, stabilization and progression, respectively. The median EDSS scores observed over 1-year follow-up after transplantation (5.5–7.0) were consistently lower than the baseline (8.0). The progression-free survival rate was 74, 65 and 48% at 3, 6 and 9 years post-transplant. 58% cases (7/12) had active lesions at baseline and all turned to inactive status in the years of follow-up. 25% cases (3/12) experienced progression after transplantation but had no active lesions in MRI over the whole follow-up period. 17% cases (2/12) without active lesions at baseline progressed active lesions in MRI. The major early toxicity resulted in fever and late toxicity caused transplantation-related mortality due to severe pneumonia and varicella-zoster virus hepatitis, respectively. AHSCT is a feasible treatment for severe MS and its long-term efficacy is favorable.
Similar content being viewed by others
References
Cheng Q, Miao L, Zhang J et al (2007) A population-based survey of multiple sclerosis in Shanghai. China Neurol 68:1495–1500
Fassas A, Anagnostopoulos A, Kazis A et al (1997) Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 20:631–638
Muraro PA, Abrahamsson SV (2010) Resetting autoimmunity in the nervous system: the role of hematopoietic stem cell transplantation. Curr Opin Investig Drugs 11:1265–1275
Van Wijmeersch B, Sprangers B, Dubois B et al (2008) Autologous and allogeneic hematopoietic stem cell transplantation for multiple sclerosis: perspective on mechanisms of action. J Neuroimmunol 197:89–98
Mezey E, Key S, Vogelsang G et al (2003) Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci 100:1364–1369
Brazelton TR, Rossi FM, Keshet GI et al (2000) From marrow to brain: expression of neuronal phenotypes in adult mice. Science 290:1775–1779
Mancardi G, Saccardi R (2008) Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 7:626–636
Ni XS, Ouyang J, Zhu WH et al (2006) Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 20:485–489
van Bekkum DW (2004) Autologous stem cell transplantation in animal models of autoimmune diseases. In: Burt RK, Marmont AM (eds) Stem cell therapy for immune diseases. Landes Biosciences, Georgetown, pp 237–244
Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517
Saiz A, Saccardi R, Mancardi GL et al (2008) Autologous HSCT for severe progressive multiple sclerosis in the Italian prospective, multicentre GITMO-Neuro trial: long term follow-up. Bone Marrow Transplant 41:S17
Saiz A, Blanco Y, Berenguer J et al (2008) Clinical outcome 6 years after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurologia 23:405–407
Saccardi R, Kozak T, Bocelli-Tyndall C et al (2006) Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for blood and marrow transplantation autoimmune diseases working party database. Mult Scler 12:814–823
Comi G, Kappos L, Clanet M et al (2000) Guideline for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for blood and marrow transplantation and the European Charcot Foundation. J Neurol 247:376–382
Burt RK, Loh Y, Cohen B et al (2009) Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 8:244–253
Fagius J, Lundgren J, Oberg G (2009) Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 15:229–237
Matthews WB (1991) Clinical aspects. Course and prognosis. In: Matthews WB (ed) McAlpine’s multiple sclerosis, second edition edn. Churchill Livingstone, Edinburgh, pp 139–163
Mancardi GL, Murialdo A, Rossi P et al (2005) Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 11:367–371
Havrdova E (2005) Aggressive multiple sclerosis—is there a role for stem cell transplantation? J Neurol 252:III34–III37
Kimiskidis V, Sakellari I, Tsimourtou V et al (2008) Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Mult Scler 14:278–283
Burt RK, Cohen B, Rose J et al (2005) Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62:860–864
ASTIMS “Autologous Stemcell Transplantation International Multiple Sclerosis trial”. http://www.astims.org
Krasulová E, Trneny M, Kozák T et al (2010) High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 16:685–693
Mancardi GL, Saccardi R, Filippi M et al (2001) Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:62–68
Saiz A, Blanco Y, Carreras E et al (2004) Clinical and MRI outcome after autologous hemtopoietic stem cell transplantation in MS. Neurology 62:282–284
Fassas A, Kimiskidis VK, Sakellari I et al (2011) Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76:1066–1070
Zivadinov R, Bakshi R (2004) Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 14:27–35
Acknowledgment
This work was supported by the Project of Jiangsu Province’s Laboratory of Clinical Immunology (NO.2003-19).
Author information
Authors and Affiliations
Corresponding author
Additional information
M. Zhou and B. Chen contribute equally to this article and should be considered as co-first authors.
Rights and permissions
About this article
Cite this article
Chen, B., Zhou, M., Ouyang, J. et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci 33, 881–886 (2012). https://doi.org/10.1007/s10072-011-0859-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-011-0859-y